Authors
Daniel Gomez-Carrillo, Rachael Caretti, Niranjna Swaminathan, Julia Kasmirski, Azeem Izhar, Raj Roy, Hameeda Arif Arain, Varun Pathak, Peter Abraham, Andrea Gillis, Brenessa Lindeman, Sophie Dream, Herbert Chen
Published in
Surgery. Pages 110818. Nov 06, 2026. Epub Nov 06, 2026.
Abstract
Thiazide diuretics are a common cause of hypercalcemia and can mask the manifestation of primary hyperparathyroidism. We aimed to determine the prevalence of primary hyperparathyroidism among patients with presumed thiazide-induced hypercalcemia.
We performed a retrospective cohort study (2005-2025) using a federated electronic health record network. Adults with ≥2 serum calcium values >10.5 mg/dL after ≥1 month of thiazide use were identified. Patients with alternative causes of hypercalcemia were excluded. We quantified the rate of parathyroid hormone testing and the prevalence of primary hyperparathyroidism, defined as inappropriately elevated parathyroid hormone (>50 pg/mL) in the setting of hypercalcemia. Treated and untreated patients were compared using 1:1 propensity score matching. Outcomes were incident fractures, osteoporosis/osteopenia, and nephrolithiasis.
We identified 268,700 patients with 2 or more instances of hypercalcemia after thiazide initiation. After exclusions, 98,554 patients were at risk for primary hyperparathyroidism. Only 39% (n = 38,350) underwent parathyroid hormone assessment. Among those tested, 56% (n = 21,286) had biochemical findings consistent with primary hyperparathyroidism, representing at least 22% of the entire at-risk cohort. The mean age was 66 ± 10 years; 75% were female, and 60% were White. Just 4% (n = 815) underwent parathyroidectomy. After propensity score matching (n = 805 per group), untreated patients had a significantly higher risk of developing bone disease compared with treated patients (risk ratio, 1.70; 95% confidence interval, 1.15-2.51). No significant differences were observed for fractures (risk ratio, 1.48; 95% confidence interval, 0.99-2.20) or nephrolithiasis (risk ratio, 1.61; 95% confidence interval, 0.96-2.70) between groups.
In patients who develop multiple instances of hypercalcemia while on thiazides, primary hyperparathyroidism is infrequently screened for and even less often treated, representing a missed opportunity to intervene and avert long-term sequelae of primary hyperparathyroidism.
PMID:
43052167
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0